Cargando…

Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-associated deaths worldwide. Treatment with immune checkpoint antibodies has shown promise in advanced HCC, but the response is only 15–20%. We discovered a potential target for the treatment of HCC, the cholecystokinin-B receptor (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shivapurkar, Narayan, Gay, Martha D., He, Aiwu (Ruth), Chen, Wenqiang, Golnazar, Shermineh, Cao, Hong, Duka, Tetyana, Kallakury, Bhaskar, Vasudevan, Sona, Smith, Jill P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965856/ https://www.ncbi.nlm.nih.gov/pubmed/36835036 http://dx.doi.org/10.3390/ijms24043625

Ejemplares similares

Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome
por: Gay, Martha D., et al.
Publicado: (2022)

Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic
por: Jolly, Gurbani, et al.
Publicado: (2023)

A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma
por: Tucker, Robin D., et al.
Publicado: (2019)

Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment
por: Hsu, Christine C., et al.
Publicado: (2022)

4119 Cholecystokinin (CCK) Receptor Antagonist Reverses Nonalcoholic Steatohepatitis (NASH) by Reducing Hepatic Macrophages and Inflammatory Cytokines
por: Gay, Martha, et al.
Publicado: (2020)

25380 Cholecystokinin-B Receptor -Mediates Growth of Hepatocellular Carcinoma
por: Gay, Martha Dee, et al.
Publicado: (2021)

Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non‐alcoholic Steatohepatitis
por: Rabiee, Atoosa, et al.
Publicado: (2022)

Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment
por: Malchiodi, Zoe X., et al.
Publicado: (2021)

Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer
por: Burks, Julian, et al.
Publicado: (2018)

Target-Specific Nanoparticle Polyplex Down-Regulates Mutant Kras to Prevent Pancreatic Carcinogenesis and Halt Tumor Progression
por: Smith, Jill P., et al.
Publicado: (2023)

4121 The beneficial, anti-fibrotic effects of chemokine receptor 2 and 5 antagonists on fat-exposed mouse primary hepatic stellate cells (pHSCs)
por: Kruger, Annie J., et al.
Publicado: (2020)

Inhibitory effect of a cholecystokinin antagonist on pancreatic carcinogenesis after pancreatobiliary diversion.
por: Watanapa, P., et al.
Publicado: (1993)

Cholecystokinin Receptor Antagonist Suppresses Melanoma Growth by Inducing Apoptosis of Tumor Cells
por: Funakoshi, Atsuko, et al.
Publicado: (2022)

The Effects of Quinacrine, Proglumide, and Pentoxifylline on Seizure Activity, Cognitive Deficit, and Oxidative Stress in Rat Lithium-Pilocarpine Model of Status Epilepticus
por: Ahmad, Mohammad, et al.
Publicado: (2014)

Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib
por: Rana, Nitesh, et al.
Publicado: (2013)

Antiproliferative Effect of a Novel Cholecystokinin‐B/Gastrin Receptor Antagonist, YM022
por: Murayama, Tohru, et al.
Publicado: (1996)

Cholecystokinin and the hormone concept
por: Rehfeld, Jens F
Publicado: (2021)

The Excitatory Effect of Cholecystokinin on Colonic Motor Function via Cholecystokinin(1) Receptor
por: Jun, Jae Yeoul
Publicado: (2011)

Cholecystokinin Activation of Cholecystokinin 1 Receptors: a Purkinje Cell Neuroprotective Pathway
por: Orr, Harry T.
Publicado: (2022)

Clinical effects of central antagonist of cholecystokinin-1 receptors GB-115 in patients with Generalized Anxiety Disorder
por: Dorofeeva, O., et al.
Publicado: (2022)

Cholecystokinin induces crowing in chickens
por: Shimmura, Tsuyoshi, et al.
Publicado: (2019)

Cholecystokinin receptor-1 mediates the inhibitory effects of exogenous cholecystokinin octapeptide on cellular morphine dependence
por: Wen, Di, et al.
Publicado: (2012)

Impact of central antagonist of cholecystokinin-1 receptors GB-115 on cognitive functions in patients with Generalized Anxiety Disorder
por: Dorofeeva, O., et al.
Publicado: (2022)

Serum cholecystokinin levels can be a predictive factor for difficult cholecystectomy: Decreased cholecystokinin receptor levels
por: Utku Yılmaz, Tonguç, et al.
Publicado: (2022)

Novel H(2)S donor proglumide-ADT-OH protects HUVECs from ox-LDL-induced injury through NF-κB and JAK/SATA pathway
por: Ou, Xuelan, et al.
Publicado: (2021)

Dual pathways of internalization of the cholecystokinin receptor
Publicado: (1995)

Oxytocin and cholecystokinin secretion in women with colectomy
por: Ohlsson, Bodil, et al.
Publicado: (2004)

Cholecystokinin Elevates Mouse Plasma Lipids
por: Zhou, Lichun, et al.
Publicado: (2012)

Cholecystokinin Expression in the Development of Myocardial Hypertrophy
por: Han, Zhongshu, et al.
Publicado: (2021)

Cholecystokinin-B Receptor-Targeted Nanoparticle for Imaging and Detection of Precancerous Lesions in the Pancreas
por: Smith, Jill P., et al.
Publicado: (2021)

In vivo and in vitro role of cholecystokinin in nitric oxide
por: Saia, R Simone, et al.
Publicado: (2010)

Sensitivity of cholecystokinin receptors to membrane cholesterol content
por: Desai, Aditya J., et al.
Publicado: (2012)

The Role of Cholecystokinin in Peripheral Taste Signaling in Mice
por: Yoshida, Ryusuke, et al.
Publicado: (2017)

Permanent Photodynamic Activation of the Cholecystokinin 2 Receptor
por: Tang, Wen Zhu, et al.
Publicado: (2020)

Premises for Cholecystokinin and Gastrin Peptides in Diabetes Therapy
por: Rehfeld, Jens F
Publicado: (2019)

2297: Dietary fat stimulates growth of pancreatic cancer growth through the cholecystokinin receptor
por: Nadella, Sandeep, et al.
Publicado: (2018)

Cholecystokinin Plays a Novel Protective Role in Diabetic Kidney Through Anti-inflammatory Actions on Macrophage: Anti-inflammatory Effect of Cholecystokinin
por: Miyamoto, Satoshi, et al.
Publicado: (2012)

SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma
por: Lin, Ling, et al.
Publicado: (2021)

Pancreatic carcinogenesis-enhancement by cholecystokinin in the hamster-nitrosamine model.
por: Howatson, A. G., et al.
Publicado: (1985)

Cholecystokinin Revisited: CCK and the Hunger Trap in Anorexia Nervosa
por: Cuntz, Ulrich, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_lb0u0dd01pbha4mt2bkhonjr2m